{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:28:22Z","timestamp":1787585302657,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jacl.2023.12.003","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T07:26:19Z","timestamp":1702625179000},"page":"e132-e141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Modern approaches to the management of homozygous familial hypercholesterolemia in the Middle East and North Africa"],"prefix":"10.1016","volume":"18","author":[{"given":"Abdullah","family":"Al-Ashwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afaf","family":"Alsagheir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al Dubayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutaz","family":"Al-Khnifsawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Sarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhier","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawfeg","family":"Ben-Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0228-1304","authenticated-orcid":false,"given":"Saif","family":"Al-Yaarubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angham","family":"Almutair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhadi","family":"Habeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6914-0730","authenticated-orcid":false,"given":"Naji","family":"Kholaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2023.12.003_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad197","article-title":"Update on European atherosclerosis society consensus statement on homozygous familial Hypercholesterolaemia: new treatments and clinical guidance","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2023.12.003_bib0002","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.jacc.2020.03.058","article-title":"Familial hypercholesterolemia: the most common monogenic disorder in humans","volume":"75","author":"Kastelein","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0003","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2023.12.003_bib0004","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0005","first-page":"2508","article-title":"Phenotypical, clinical, and molecular aspects of adults and children with homozygous familial hypercholesterolemia in iberoamerica","volume":"40","author":"Alves","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0006","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS familial hypercholesterolaemia studies collaboration (FHSC)","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2023.12.003_bib0007","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2023.12.003_bib0008","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/1570161113666150827125040","article-title":"Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a middle east advisory panel","volume":"13","author":"Al-Ashwal","year":"2015","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2023.12.003_bib0010","first-page":"2023","article-title":"Canadian agency for drugs and technologies in health","year":"2015","journal-title":"Lomitapide (Juxtapid)"},{"key":"10.1016\/j.jacl.2023.12.003_bib0011","unstructured":"Stiles S. FDA Approves Orphan Drug Evinacumab-dgnb for Homozygous FH. Medscape 2021; Available at: https:\/\/www.medscape.com\/viewarticle\/945719. Accessed December 2023."},{"key":"10.1016\/j.jacl.2023.12.003_bib0012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11883-021-00926-3","article-title":"The mighty medic satellite research group for Pediatric D. Current approach to the diagnosis and treatment of heterozygote and homozygous FH children and adolescents","volume":"23","author":"Cohen","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2023.12.003_bib0013","unstructured":"World Heart Federation. Improving Prevention and Control of Raised Cholesterol. World Heart Federation 2021; Available at: https:\/\/world-heart-federation.org\/resource\/whf-cholesterol-white-paper\/. Accessed December 2023."},{"key":"10.1016\/j.jacl.2023.12.003_bib0014","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2018.05.047","article-title":"Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: a cost-utility analysis","volume":"275","author":"McKay","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2023.12.003_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19074418","article-title":"Knowledge and Perception of and attitude toward a premarital screening program in qatar: a cross-sectional study","volume":"19","author":"Al-Shafai","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jacl.2023.12.003_bib0016","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jsm.12824","article-title":"Sexual function and fertility quality of life in women using in vitro fertilization","volume":"12","author":"Smith","year":"2015","journal-title":"J Sex Med"},{"key":"10.1016\/j.jacl.2023.12.003_bib0017","first-page":"11","article-title":"Genetic technologies and ethics","volume":"2","author":"Ardekani","year":"2009","journal-title":"J Med Ethics Hist Med"},{"key":"10.1016\/j.jacl.2023.12.003_bib0018","doi-asserted-by":"crossref","first-page":"17248","DOI":"10.1038\/s41598-019-53655-8","article-title":"Genetic disorder prenatal diagnosis and pregnancy termination practices among high consanguinity population, Saudi Arabia","volume":"9","author":"AbdulAzeez","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jacl.2023.12.003_bib0019","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251560","article-title":"Familial hypercholesterolemia in the Arabian gulf region: clinical results of the gulf FH registry","volume":"16","author":"Alhabib","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jacl.2023.12.003_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.927504","article-title":"The prevalence and genetic spectrum of familial hypercholesterolemia in qatar based on whole genome sequencing of 14,000 subjects","volume":"13","author":"Diboun","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.jacl.2023.12.003_bib0022","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0021-9150(93)90186-X","article-title":"Phenotypic expression of familial hypercholesterolaemia in central and southern Tunisia","volume":"104","author":"Slimane","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2023.12.003_bib0023","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0024","first-page":"334","article-title":"Consanguineous marriages and some reproductive health parameters for sample from families in Baghdad, Iraq","volume":"21","author":"Lafta","year":"2010","journal-title":"Al-Mustansiriya J Sci."},{"key":"10.1016\/j.jacl.2023.12.003_bib0025","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/jmg.32.8.623","article-title":"Consanguinity among the Saudi Arabian population","volume":"32","author":"el-Hazmi","year":"1995","journal-title":"J Med Genet"},{"key":"10.1016\/j.jacl.2023.12.003_bib0026","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4314\/ahs.v14i2.5","article-title":"Is consanguinity prevalence decreasing in Saudis?: a study in two generations","volume":"14","author":"Warsy","year":"2014","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.jacl.2023.12.003_bib0027","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-genom-083118-014954","article-title":"Consanguinity and Inbreeding in Health and Disease in North African Populations","volume":"20","author":"Romdhane","year":"2019","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.jacl.2023.12.003_bib0028","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-021-01720-y","article-title":"Homozygous familial hypercholesterolemia (HoFH) in Saudi Arabia and two cases of lomitapide use in a real-world setting","author":"Mahzari","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2023.12.003_bib0029","doi-asserted-by":"crossref","first-page":"14021","DOI":"10.1038\/hgv.2014.21","article-title":"Identification of a novel nonsense variant c.1332dup, p.(D445*) in the LDLR gene that causes familial hypercholesterolemia","volume":"1","author":"Al-Allaf","year":"2014","journal-title":"Hum Genome Var"},{"key":"10.1016\/j.jacl.2023.12.003_bib0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2018.10.022","article-title":"Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries","volume":"279","author":"Alhababi","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2023.12.003_bib0031","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J Atheroscler Thromb"},{"issue":"Suppl 5","key":"10.1016\/j.jacl.2023.12.003_bib0032","first-page":"S213","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacl.2023.12.003_bib0033","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0034","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.acap.2016.06.005","article-title":"Universal cholesterol screening in childhood: a systematic review","volume":"16","author":"Smith","year":"2016","journal-title":"Acad Pediatr"},{"key":"10.1016\/j.jacl.2023.12.003_bib0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MOL.0000000000000853","article-title":"New algorithms for treating homozygous familial hypercholesterolemia","volume":"33","author":"Tromp","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0036","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","article-title":"Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes","volume":"57","author":"Cheung","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0037","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.jacl.2023.12.003_bib0038","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is niemann-pick C1-Like 1 (NPC1L1)","volume":"102","author":"Garcia-Calvo","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2023.12.003_bib0039","doi-asserted-by":"crossref","first-page":"243","DOI":"10.12968\/bjcn.2015.20.5.243","article-title":"The IMPROVE-IT study and ezetimibe","volume":"20","author":"Signy","year":"2015","journal-title":"Br J Community Nurs"},{"key":"10.1016\/j.jacl.2023.12.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221100107","article-title":"A comprehensive review of PCSK9 inhibitors","volume":"27","author":"Coppinger","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jacl.2023.12.003_bib0041","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0042","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH Trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0043","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2023.12.003_bib0044","doi-asserted-by":"crossref","DOI":"10.5551\/jat.CR006","article-title":"Joint Working Group of the Japan Pediatric S and the Japan atherosclerosis society for the development of guidelines for pediatric familial H. Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022","author":"Harada-Shiba","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2023.12.003_bib0045","doi-asserted-by":"crossref","DOI":"10.4081\/monaldi.2023.2503","article-title":"Management and clinical outcomes of patients with homozygous familial hypercholesteremia in Saudi Arabia","author":"Kholaif","year":"2023","journal-title":"Monaldi Arch Chest Dis."},{"key":"10.1016\/j.jacl.2023.12.003_bib0046","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2023.12.003_bib0047","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11886-021-01565-5","article-title":"Familial hypercholesterolemia: global burden and approaches","volume":"23","author":"Tokgozoglu","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacl.2023.12.003_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2019.02.001","article-title":"Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: results of a nationwide survey (A-HIT1 registry)","author":"Kayikcioglu","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0049","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-021-01999-8","article-title":"Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey","volume":"16","author":"D'Erasmo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacl.2023.12.003_bib0050","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1007\/s12325-022-02131-3","article-title":"Is liver transplant curative in homozygous familial hypercholesterolemia? A review of nine global cases","volume":"39","author":"Al Dubayee","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2023.12.003_bib0051","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s12325-019-00985-8","article-title":"Real-world outcomes with lomitapide use in Paediatric patients with homozygous familial hypercholesterolaemia","volume":"36","author":"Ben-Omran","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2023.12.003_bib0052","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2023.12.003_bib0053","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Italian and European working group on lomitapide in Ho FH. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0054","article-title":"Evaluation of long-term efficacy and safety of lomitapide in homozygous familial hypercholesterolemia: real-world evidence from the pan-European observational study","author":"D'Erasmo","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Rader DJ and Phase 3 Ho FHLSi. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2023.12.003_bib0056","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CE.S174169","article-title":"Lomitapide: a review of its clinical use, efficacy, and tolerability","volume":"14","author":"Alonso","year":"2019","journal-title":"Core Evid"},{"key":"10.1016\/j.jacl.2023.12.003_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the lomitapide observational worldwide evaluation registry (LOWER)","author":"Underberg","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0058","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","article-title":"Lomitapide-a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia","volume":"22","author":"Stefanutti","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2023.12.003_bib0059","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/liv.15497","article-title":"Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia","volume":"43","author":"Larrey","year":"2022","journal-title":"Liver International"},{"key":"10.1016\/j.jacl.2023.12.003_bib0060","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14712598.2022.2090242","article-title":"Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia","volume":"22","author":"Pirillo","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jacl.2023.12.003_bib0061","first-page":"15","article-title":"Long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia: real-world clinical experience","author":"Stefanutti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jacl.2023.12.003_bib0062","series-title":"Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients \u2013 results from the efficacy phase of the APH-19 study","author":"Masana","year":"2023"},{"key":"10.1016\/j.jacl.2023.12.003_bib0063","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fca-2021-0149","article-title":"Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia","volume":"18","author":"Khoury","year":"2022","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0064","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","author":"Wiegman","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2023.12.003_bib0065","first-page":"16","article-title":"Current treatment options in homozygous familial hypercholesterolemia","author":"Kayikcioglu","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jacl.2023.12.003_bib0066","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2023.12.003_bib0067","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10051043","article-title":"Recent advances on familial hypercholesterolemia in children and adolescents","volume":"10","author":"Mainieri","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.jacl.2023.12.003_bib0068","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2023.12.003_bib0069","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5334\/gh.759","article-title":"Xanthomas can be misdiagnosed and mistreated in homozygous familial hypercholesterolemia patients: a call for increased awareness among dermatologists and health care practitioners","volume":"15","author":"Alnouri","year":"2020","journal-title":"Glob Heart"},{"key":"10.1016\/j.jacl.2023.12.003_bib0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pepo.2013.11.006","article-title":"Corneal arcus as the first presentation of hypercholesterolemia in children","volume":"89","author":"Panahi-Bazaz","year":"2014","journal-title":"Ped Pol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183494","article-title":"Assessment of physicians' awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: is there a gap?","volume":"12","author":"Batais","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jacl.2023.12.003_bib0072","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.4103\/jfmpc.jfmpc_285_19","article-title":"Assessment of family physicians' awareness and knowledge of familial hypercholesterolemia in governmental hospitals in Riyadh, Saudi Arabia","volume":"8","author":"Arnous","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.jacl.2023.12.003_bib0073","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12944-020-01266-y","article-title":"Assessment of medical intern's knowledge, awareness and practice of familial hypercholesterolemia at academic institutes in Jeddah, Saudi Arabia","volume":"19","author":"Alzahrani","year":"2020","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2023.12.003_bib0074","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0735-1097(23)02200-3","article-title":"Effectiveness of micro CME at improving clinician knowledge and competence related to early detection and treatment of homozygous familial hypercholesterolemia","volume":"81","author":"Harris","year":"2023","journal-title":"J Am Cool Cardiol"},{"key":"10.1016\/j.jacl.2023.12.003_bib0075","unstructured":"Amryt Pharmaceuticals DAC. Lojuxta summary of product characteristics. 2022."},{"key":"10.1016\/j.jacl.2023.12.003_bib0076","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006385","volume":"5","author":"Afshin","year":"2015","journal-title":"BMJ Open"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423003525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423003525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T22:34:30Z","timestamp":1714602870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287423003525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1933287423003525"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2023.12.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern approaches to the management of homozygous familial hypercholesterolemia in the Middle East and North Africa","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2023.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}